Thrombus causes fluctuations in arterial drug delivery from intravascular stents

Journal of Controlled Release

Volumn 131, Issue 3, 2008, Pages 173-180

  Balakrishnan, Brinda ^a   Dooley, John ^b   Kopia, Gregory ^b   Edelman, Elazer R ^a,c  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Department of Medical Affairs and Health Ecomomics Worldwide   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Drug delivery; Restenosis; Stents; Thrombus

Indexed keywords

ARTIFICIAL ORGANS; FORECASTING;

ARTERIAL DRUG DELIVERIES; DRUG CONCENTRATIONS; DRUG DIFFUSIONS; DRUG RELEASES; DRUG TRANSPORTS; DRUG UPTAKES; DRUG-ELUTING STENTS; IN-VIVO; INTRAVASCULAR STENTS; PORCINE CORONARY ARTERIES; RELEASE KINETICS; RESTENOSIS; SAFETY CONCERNS; STENT IMPLANTATIONS; STENTS; THROMBUS;

DRUG DELIVERY;

RAPAMYCIN;

ACTIVE TRANSPORT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY THROMBOSIS; ARTICLE; CORONARY ARTERY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG ELUTING STENT; DRUG RELEASE; DRUG TRANSPORT; DRUG UPTAKE; MATHEMATICAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; SWINE; THROMBUS;

ANIMALS; BLOOD VESSEL PROSTHESIS IMPLANTATION; CARDIOVASCULAR AGENTS; CORONARY RESTENOSIS; CORONARY VESSELS; DRUG DELIVERY SYSTEMS; DRUG-ELUTING STENTS; SIROLIMUS; SWINE; SWINE, MINIATURE; THROMBOSIS; TIME FACTORS;

EID: 54049104287     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2008.07.027     Document Type: Article

References (38)

1. Daemen J., Wenaweser P., Tsuchida K., Abrecht L., Vaina S., Morger C., Kukreja N., Juni P., Sianos G., Hellige G., van Domburg R.T., Hess O.M., Boersma E., Meier B., Windecker S., and Serruys P.W. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 9562 (2007) 667-678
2. Carlsson J., von Wagenheim B., Linder R., Anwari T.M., Qvist J., Petersson I., Magounakis T., and Lagerqvis B. Is late stent thrombosis in drug-eluting stents a real clinical issue? A single-center experience and review of the literature. Clin. Res. Cardiol. (2006)
3. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., Rickenbacher P., Hunziker P., Mueller C., Jeger R., Bader F., Osswald S., and Kaiser C. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J. Am. Coll. Cardiol. 48 12 (2006) 2584-2591
4. Drachman D.E., Edelman E.R., Seifert P., Groothuis A.R., Bornstein D.A., Kamath K.R., Palasis M., Yang D., Nott S.H., and Rogers C. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J. Am. Coll. Cardiol. 36 7 (2000) 2325-2332
5. Farb A., Heller P.F., Shroff S., Cheng L., Kolodgie F.D., Carter A.J., Scott D.S., Froehlich J., and Virmani R. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 104 4 (2001) 473-479
6. Sousa J.E., Costa M.A., Farb A., Abizaid A., Sousa A., Seixas A.C., da Silva L.M., Feres F., Pinto I., Mattos L.A., and Virmani R. Images in cardiovascular medicine. Vascular healing 4 years after the implantation of sirolimus-eluting stent in humans: a histopathological examination. Circulation 110 1 (2004) e5-6
7. Hofma S.H., van der Giessen W.J., van Dalen B.M., Lemos P.A., McFadden E.P., Sianos G., Ligthart J.M., van Essen D., de Feyter P.J., and Serruys P.W. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur. Heart. J. 27 2 (2006) 166-170
8. Togni M., Windecker S., Cocchia R., Wenaweser P., Cook S., Billinger M., Meier B., and Hess O.M. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J. Am. Coll. Cardiol. 46 2 (2005) 231-236
9. Axel D.I., Kunert W., Goggelmann C., Oberhoff M., Herdeg C., Kuttner A., Wild D.H., Brehm B.R., Riessen R., Koveker G., and Karsch K.R. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96 2 (1997) 636-645
10. Matter C.M., Rozenberg I., Jaschko A., Greutert H., Kurz D.J., Wnendt S., Kuttler B., Joch H., Grunenfelder J., Zund G., Tanner F.C., and Luscher T.F. Effects of tacrolimus or sirolimus on proliferation of vascular smooth muscle and endothelial cells. J. Cardiovasc. Pharmacol. 48 6 (2006) 286-292
11. Balakrishnan B., Dooley J.F., Kopia G., and Edelman E.R. Intravascular drug release kinetics dictate arterial drug deposition, retention, and distribution. J. Control. Release 123 2 (2007) 100-108
12. Westedt U., Kalinowski M., Wittmar M., Merdan T., Unger F., Fuchs J., Schaller S., Bakowsky U., and Kissel T. Poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) nanoparticles for local delivery of paclitaxel for restenosis treatment. J. Control. Release. 119 1 (2007) 41-51
13. Westedt U., Wittmar M., Hellwig M., Hanefeld P., Greiner A., Schaper A.K., and Kissel T. Paclitaxel releasing films consisting of poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) and their potential as biodegradable stent coatings. J. Control. Release. 111 1-2 (2006) 235-246
14. Zweers M.L., Engbers G.H., Grijpma D.W., and Feijen J. Release of anti-restenosis drugs from poly(ethylene oxide)-poly(dl-lactic-co-glycolic acid) nanoparticles. J. Control. Release 114 3 (2006) 317-324
15. Huh K.M., Lee S.C., Cho Y.W., Lee J., Jeong J.H., and Park K. Hydrotropic polymer micelle system for delivery of paclitaxel. J. Control. Release 101 1-3 (2005) 59-68
16. Hwang C.W., Levin A.D., Jonas M., Li P.H., and Edelman E.R. Thrombosis modulates arterial drug distribution for drug-eluting stents. Circulation 111 13 (2005) 1619-1626
17. Diaz-Sandoval L.J., Bouma B.E., Tearney G.J., and Jang I.K. Optical coherence tomography as a tool for percutaneous coronary interventions. Catheter. Cardiovasc. Interv. 65 4 (2005) 492-496
18. Toschi V., Gallo R., Lettino M., Fallon J.T., Gertz S.D., Fernandez-Ortiz A., Chesebro J.H., Badimon L., Nemerson Y., Fuster V., and Badimon J.J. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 95 3 (1997) 594-599
19. Wilcox J.N., Smith K.M., Schwartz S.M., and Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc. Natl. Acad. Sci. U. S. A. 86 8 (1989) 2839-2843
20. Ruef J., Kranzhofer R., and Kranzhofer R. Coronary stent thrombosis related to aspirin resistance: what are the underlying mechanisms. J. Interv. Cardiol. 19 6 (2006) 507-509
21. Steffel J., Latini R.A., Akhmedov A., Zimmermann D., Zimmerling P., Luscher T.F., and Tanner F.C. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation 112 13 (2005) 2002-2011
22. Rogers C., and Edelman E.R. Endovascular stent design dictates experimental restenosis and thrombosis. Circulation 91 12 (1995) 2995-3001
23. Rogers C., Tseng D.Y., Squire J.C., and Edelman E.R. Balloon-artery interactions during stent placement: a finite element analysis approach to pressure, compliance, and stent design as contributors to vascular injury. Circ. Res. 84 4 (1999) 378-383
24. Rogers C., Parikh S., Seifert P., and Edelman E.R. Endogenous cell seeding. Remnant endothelium after stenting enhances vascular repair. Circulation 94 11 (1996) 2909-2914
25. Jeremias A., Sylvia B., Bridges J., Kirtane A.J., Bigelow B., Pinto D.S., Ho K.K., Cohen D.J., Garcia L.A., Cutlip D.E., and Carrozza Jr. J.P. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 109 16 (2004) 1930-1932
26. Balakrishnan B., Tzafriri A.R., Seifert P., Groothuis A., Rogers C., and Edelman E.R. Strut position, blood flow, and drug deposition: implications for single and overlapping drug-eluting stents. Circulation 111 22 (2005) 2958-2965
27. Deen W.M. Analysis of Transport Phenomena (1998), Oxford University Press, Inc, Oxford
28. In: Berne R., and Levy M.N. (Eds). Physiology. 4 ed (1998), Mosby, Inc., St. Louis
29. Hwang C.W., and Edelman E.R. Arterial ultrastructure influences transport of locally delivered drugs. Circ. Res. 90 7 (2002) 826-832
30. Levin A.D., Vukmirovic N., Hwang C.W., and Edelman E.R. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc. Natl. Acad. Sci. U. S. A. 101 25 (2004) 9463-9467
31. Sianos G., Papafaklis M.I., Daemen J., Vaina S., van Mieghem C.A., van Domburg R.T., Michalis L.K., and Serruys P.W. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J. Am. Coll. Cardiol. 50 7 (2007) 573-583
32. Hwang C.W., Wu D., and Edelman E.R. Physiological transport forces govern drug distribution for stent-based delivery. Circulation 104 5 (2001) 600-605
33. Lovich M.A., Creel C., Hong K., Hwang C.W., and Edelman E.R. Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel. J. Pharm. Sci. 90 9 (2001) 1324-1335
34. Ramirez C.A., Colton C.K., Smith K.A., Stemerman M.B., and Lees R.S. Transport of 125I-albumin across normal and deendothelialized rabbit thoracic aorta in vivo. Arteriosclerosis 4 3 (1984) 283-291
35. Paal K., Muller J., and Hegedus L. High affinity binding of paclitaxel to human serum albumin. Eur. J. Biochem. 268 7 (2001) 2187-2191
36. Lovich M.A., and Edelman E.R. Mechanisms of transmural heparin transport in the rat abdominal aorta after local vascular delivery. Circ. Res. 77 6 (1995) 1143-1150
37. Klugherz B.D., Llanos G., Lieuallen W., Kopia G.A., Papandreou G., Narayan P., Sasseen B., Adelman S.J., Falotico R., and Wilensky R.L. Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent. Coron. Artery. Dis. 13 3 (2002) 183-188
38. Stahli B.E., Camici G.G., Steffel J., Akhmedov A., Shojaati K., Graber M., Luscher T.F., and Tanner F.C. Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation. Circ. Res. 99 2 (2006) 149-155